People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evofem Biosciences, Inc. | — | Biotechnology | Series B | $133.6M | $4.3M | 2019 |
| Aria Diagnostics, Inc. | — | Biotechnology | Series C | $65.2M | $2.2B | 2011 |
| Alume Biosciences Inc | — | Biotechnology | Series A | $33.4M | $18.9M | 2022 |
| Nuon Therapeutics Inc | — | Biotechnology | Series A | $29.7M | $361.5M | 2009 |
| Rox Medical Inc | — | Other Health Care | Series A | $20.5M | $112.1M | 2011 |
| Altair Therapeutics, Inc. | — | Biotechnology | Series A | $6.5M | $233.8M | 2009 |
Kim Kamdar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kim Kamdar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bryan Roberts | 1 | 18 |
| Ivor Royston | 1 | 7 |
| Thomas Lynch | 1 | 7 |
| Guido Neels | 1 | 7 |
| Robert More | 1 | 7 |
| Jason Brown | 1 | 7 |
| Magda Marquet | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Bob More | 1 | 6 |
| Pratik Shah | 1 | 5 |
| Joel Martin | 1 | 5 |
| William Hall | 1 | 5 |
| Arlene Morris | 1 | 5 |
| Kevin Wasserstein | 1 | 5 |
| David Shapiro | 1 | 4 |
| Jean-Pierre Millon | 1 | 3 |
| James Schmidt | 1 | 3 |
| John Stuelpnagel | 1 | 3 |
| Dan Bradbury | 1 | 3 |
| Joshua Funder | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.